Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,258 signal articles · 39 in last 24h · 115,255 total before filter · latest 2h ago
39last 24h
1802last 7d
299● bullish (7d)
170● bearish (7d)
205publishers
AllMacro322Earnings851M&A104Regulatory25Product16Analyst25
✕ clear all filtersticker: TDOCSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
TDOC Q2 Deep Dive: Cash Pay Decline and Insurance Shift Pressure Guidance
StockStory11d agoneutral
TDOC Q2 Deep Dive: Cash Pay Decline and Insurance Shift Pressure Guidance

Digital medical services platform Teladoc Health (NYSE:TDOC) missed Wall Street’s revenue expectations in Q2 CY2026, with sales falling 4% year on year to $606.9 million. Next quarter’s revenue guidance of $589 million underwhelmed, coming in 6.5% below analysts’ estimates. Its GAAP loss of $0.21 per share was 15.5% above analysts’ consensus estimates.

Teladoc Health Q2 Earnings Call Highlights
MarketBeat16d agoneutral
Teladoc Health Q2 Earnings Call Highlights

Teladoc Health (NYSE:TDOC) reported second-quarter results within its consolidated guidance range, supported by stronger-than-expected profitability in its Integrated Care segment, while lower cash-pay revenue at BetterHelp prompted the company to reduce its full-year revenue outlook. Consolidated

Teladoc Health (TDOC) Stock Valuation As Analyst Sentiment Improves Despite Expected Earnings Decline
Simply Wall St.62d agoneutral
Teladoc Health (TDOC) Stock Valuation As Analyst Sentiment Improves Despite Expected Earnings Decline

Analyst sentiment shift and near term expectations Teladoc Health (TDOC) is back on investors’ radar after analysts turned more positive in their earnings estimates, even as they still expect a 26.32% year over year decline in the upcoming report. This change in sentiment, paired with a recent 1.44% gain that outperformed key indices, has focused attention on how the company’s virtual care and mental health businesses might shape near term performance. See our latest analysis for Teladoc...

Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead
24/7 Wall St.89d agobearish
Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead

Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead

Teladoc Health Q1 Earnings Call Highlights
MarketBeat105d agoneutral
Teladoc Health Q1 Earnings Call Highlights

Teladoc Health (NYSE:TDOC) reported first-quarter 2026 results that Chief Executive Officer Chuck Divita said came in above the midpoint of the company’s guidance for both revenue and Adjusted EBITDA, driven by solid performance in Integrated Care and continued progress scaling BetterHelp’s insuranc